OncoSec Medical Inc (NASDAQ:ONCS) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 240,300 shares, an increase of 42.4% from the July 31st total of 168,800 shares. Currently, 4.5% of the shares of the company are sold short. Based on an average daily volume of 154,200 shares, the short-interest ratio is presently 1.6 days.
OncoSec Medical stock traded up $0.06 during mid-day trading on Friday, reaching $2.00. The company’s stock had a trading volume of 53,039 shares, compared to its average volume of 112,879. OncoSec Medical has a 12-month low of $1.80 and a 12-month high of $19.60. The firm’s fifty day moving average price is $2.06 and its two-hundred day moving average price is $1.58.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Friday, June 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.34. On average, equities research analysts forecast that OncoSec Medical will post -5.27 EPS for the current year.
In related news, Director Alpha Holdings, Inc. purchased 90,000 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was bought at an average price of $2.30 per share, for a total transaction of $207,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC purchased a new position in OncoSec Medical in the 2nd quarter valued at approximately $27,000. Citadel Advisors LLC purchased a new position in OncoSec Medical in the 2nd quarter valued at approximately $33,000. JPMorgan Chase & Co. purchased a new position in OncoSec Medical in the 2nd quarter valued at approximately $46,000. Worth Venture Partners LLC bought a new position in OncoSec Medical in the 2nd quarter valued at $99,000. Finally, Geode Capital Management LLC boosted its holdings in OncoSec Medical by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 163,405 shares during the period. Institutional investors and hedge funds own 5.83% of the company’s stock.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.